Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Reduced Intensity Conditioning Leads to Less Transplant-Related Mortality for Older Patients With MDS

March 8, 2022
By Ronald L. Paquette, MD
Video

Ronald L. Paquette, MD, discusses how transplant related morbidity and mortality risks differ between age groups for patients with myelodysplastic syndrome.

Ronald L. Paquette, MD, clinical director, Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, discusses the transplant related morbidity and mortality risks and how they differ between the age groups for patients with myelodysplastic syndrome (MDS).

According to Paquette, patients with MDS are generally older. His research has shown transplant related mortality for older individuals to be consistent with previous data when using a reduced intensity conditioning regimen.

Fludarabine with total body radiation at a dose of 800 cGy is the current preferred regimen used to treat these patients, but the safety and efficacy are continuously being examined to make sure this method is best.

Transcription:

0:08 | Myelodysplastic syndrome patients in general are older. I'm gearing my discussion primarily to the older age group MDS, and of course MDS can happen in younger patients to where there are less concerns about conditioning related morbidity and mortality. What we found is that our transplant related mortality for older individuals is still less than 10% using a reduced intensity conditioning regimen. I think that's reassuring.

0:44 | What we found however, is that because we're using post-transplant cyclophosphamide as graft versus host disease prophylaxis, the use of alkylating agents as part of the conditioning regimen has led to undue toxicities not just in older age group, but even in younger patients. In our hands, Northland and the conditioning regimen is associated with thrombotic microangiopathy in some patients at a rate that's higher than the use of total body irradiation. We also see pulmonary toxicity with the use of alkylating agents in the conditioning regimen.

1:25 | Our go to regimen in older individuals is fludarabine with total body radiation at a dose of 800 cGy. That's been our preference recently. We are obviously monitoring the safety and efficacy of this regimen going forward. But we've been able to mitigate the risks of those two particular complications that we previously saw with melphalan containing regimens.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content

Exploring the Treatment Landscape in Chronic GVHD

Exploring the Treatment Landscape in Chronic GVHD

Tony Berberabe, MPH
June 24th 2025
Article

Explore the complexities of chronic GVHD symptoms, assessment, and innovative treatment strategies, including ruxolitinib and emerging therapies.

Read More


BMT CTN 1902 in Myeloma: Key Findings With Garfall

BMT CTN 1902 in Myeloma: Key Findings With Garfall

Jordyn Sava;Alfred L. Garfall, MD, MS
March 13th 2025
Podcast

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

Listen


Epcoritamab/R-ICE Shows High Response in R/R DLBCL, Aids ASCT Eligibility

Epcoritamab/R-ICE Shows High Response in R/R DLBCL, Aids ASCT Eligibility

Sabrina Serani
June 18th 2025
Article

Read More


Improved Outcomes With Cyclophosphamide/Cyclosporin for GVHD Prophylaxis in SCT

Improved Outcomes With Cyclophosphamide/Cyclosporin for GVHD Prophylaxis in SCT

Ariana Pelosci
June 18th 2025
Article

New trial data reveals cyclophosphamide plus cyclosporin significantly enhances GVHD prevention in stem cell transplant patients, offering hope for better outcomes.

Read More


ALLELE Trial Confirms Clinical Activity of Tabelecleucel in Lymphoproliferative Disease

ALLELE Trial Confirms Clinical Activity of Tabelecleucel in Lymphoproliferative Disease

Courtney Flaherty
June 17th 2025
Article

Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous therapies.

Read More


Cellular Therapies Show Safety in B-Cell Malignancies

Cellular Therapies Show Safety in B-Cell Malignancies

Caroline Seymour
June 16th 2025
Article

The safety and efficacy outcomes of a total of 3 CD19-directed CAR T-cell therapies were confirmed with other real-world data with CAR T-cell therapy in patients with B-cell malignancies.

Read More

Related Content

Exploring the Treatment Landscape in Chronic GVHD

Exploring the Treatment Landscape in Chronic GVHD

Tony Berberabe, MPH
June 24th 2025
Article

Explore the complexities of chronic GVHD symptoms, assessment, and innovative treatment strategies, including ruxolitinib and emerging therapies.

Read More


BMT CTN 1902 in Myeloma: Key Findings With Garfall

BMT CTN 1902 in Myeloma: Key Findings With Garfall

Jordyn Sava;Alfred L. Garfall, MD, MS
March 13th 2025
Podcast

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

Listen


Epcoritamab/R-ICE Shows High Response in R/R DLBCL, Aids ASCT Eligibility

Epcoritamab/R-ICE Shows High Response in R/R DLBCL, Aids ASCT Eligibility

Sabrina Serani
June 18th 2025
Article

Read More


Improved Outcomes With Cyclophosphamide/Cyclosporin for GVHD Prophylaxis in SCT

Improved Outcomes With Cyclophosphamide/Cyclosporin for GVHD Prophylaxis in SCT

Ariana Pelosci
June 18th 2025
Article

New trial data reveals cyclophosphamide plus cyclosporin significantly enhances GVHD prevention in stem cell transplant patients, offering hope for better outcomes.

Read More


ALLELE Trial Confirms Clinical Activity of Tabelecleucel in Lymphoproliferative Disease

ALLELE Trial Confirms Clinical Activity of Tabelecleucel in Lymphoproliferative Disease

Courtney Flaherty
June 17th 2025
Article

Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous therapies.

Read More


Cellular Therapies Show Safety in B-Cell Malignancies

Cellular Therapies Show Safety in B-Cell Malignancies

Caroline Seymour
June 16th 2025
Article

The safety and efficacy outcomes of a total of 3 CD19-directed CAR T-cell therapies were confirmed with other real-world data with CAR T-cell therapy in patients with B-cell malignancies.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.